

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT TUL12101 EYE DROPS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors ("the Board") of the Company is pleased to announce that the enrollment of the first subject in the Phase IIa clinical trial in China for TUL12101 Eye Drops, a Class 1 new drug independently developed by Zhuhai United Laboratories Co., Ltd., a wholly-owned subsidiary of the Company, was completed on 14 October 2024.

The trial is a multi-center, randomized, double-blind, placebo-controlled parallel trial designed to evaluate the efficacy, safety, pharmacokinetics and pharmacokinetic characteristics of TUL12101 Eye Drops for the treatment of dry eye syndrome. In May 2024, the Company completed the Phase I clinical trial on the safety, tolerability and pharmacokinetic characteristics of TUL12101 Eye Drops for single and multiple doses in healthy subjects in China, and the results showed good safety and tolerability in healthy subjects.

ABOUT DRY EYE SYNDROME AND TUL12101 EYE DROPS

Dry eye is a chronic ocular surface disease caused by multiple factors, which can be accompanied by ocular surface inflammatory response, tissue damage and nerve abnormalities, resulting in a variety of ocular discomfort symptoms and/or visual dysfunction. TUL12101 is a new generation of small molecule RASP (Reactive Aldehyde Species) inhibitor with anti-inflammatory mechanism. It can capture harmful aldehydes released during the inflammatory response to relieve inflammation and break the vicious cycle of inflammation, thereby achieving the purpose of treating dry eye syndrome and other ophthalmic diseases. At present, the Company is the first enterprise in China and the second one in the world to develop RASP inhibitors.

The Company will continue to promote the clinical trial of TUL12101 Eye Drops, and enhance the pipeline deployment and market competitiveness in the field of ophthalmic drugs. In the future, the Company will continue to commit itself to the research and development of new products, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 14 October 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.